Knowing lets her choose. Right now, she doesn't even have the option.
Por gerações, o risco hereditário de câncer de mama permaneceu invisível para milhões de brasileiros que não podiam pagar para enxergá-lo. Com a incorporação dos testes genéticos para mutações BRCA1 e BRCA2 ao SUS, o Brasil reconhece que o conhecimento sobre o próprio corpo não deve ser privilégio de quem tem dinheiro. Nos próximos 180 dias, o sistema público de saúde começará a oferecer aquilo que clínicas privadas cobram até três mil reais para revelar — a possibilidade de agir antes que o câncer se instale.
- Mutações nos genes BRCA1 e BRCA2 podem elevar o risco de câncer de mama a 80% e o de ovário a 40%, mas a maioria dos portadores brasileiros nunca soube que carregava essa herança.
- O teste de sequenciamento de nova geração custava entre R$1.000 e R$3.000 em clínicas privadas, tornando o diagnóstico precoce inacessível para a maior parte da população.
- Uma portaria federal publicada em 13 de maio determinou a inclusão do exame no SUS, dando ao governo 180 dias para estruturar a oferta em hospitais e clínicas públicas.
- Quem descobre a mutação pode optar por cirurgias preventivas e monitoramento intensivo — intervenções que reduzem a mortalidade e evitam tratamentos mais agressivos no futuro.
- A Sociedade Brasileira de Mastologia já sinalizou que quer ampliar o escopo: mais genes hereditários testados, mais aconselhamento genético e maior acesso a cirurgias preventivas pelo sistema público.
O Brasil está prestes a oferecer pelo sistema público algo que até agora pertencia quase exclusivamente a quem podia pagar: um teste genético capaz de identificar mutações nos genes BRCA1 e BRCA2, marcadores que elevam drasticamente o risco de câncer de mama e de ovário. A medida foi formalizada por portaria federal publicada em 13 de maio, e o governo tem 180 dias para torná-la realidade.
Esses dois genes funcionam como supressores de tumor — quando operam normalmente, produzem proteínas que reparam danos no DNA e impedem a multiplicação celular descontrolada. Quando uma mutação está presente, essa proteção falha. Especialistas da Sociedade Brasileira de Mastologia, que solicitou a inclusão do exame no SUS, apontam riscos de até 80% para câncer de mama e 40% para câncer de ovário em portadores das mutações.
A tecnologia usada, o sequenciamento de nova geração (NGS), não é novidade — o que muda é quem pode acessá-la. Em clínicas privadas, o exame custa entre R$1.000 e R$3.000, valores fora do alcance da maioria dos brasileiros. O caso ganhou visibilidade internacional em 2013, quando Angelina Jolie revelou ter descoberto uma mutação no BRCA1 e optado por mastectomia preventiva, mostrando ao mundo que essa não era uma preocupação rara.
A lógica da incorporação é direta: quem sabe que carrega a mutação pode escolher cirurgias de redução de risco, entrar em programas de monitoramento intensivo e tomar decisões informadas sobre o próprio futuro. Prevenir é menos destrutivo e menos custoso do que tratar. Nos próximos seis meses, hospitais e clínicas precisarão ser capacitados, equipamentos instalados e protocolos definidos. A Sociedade Brasileira de Mastologia já indica que quer ir além — ampliando o teste para outros genes hereditários e expandindo o acesso a cirurgias preventivas e aconselhamento genético dentro do SUS.
Brazil's public health system is about to offer something it never has before: a genetic test that can tell you whether you carry mutations in two genes that dramatically raise your risk of breast and ovarian cancer. The test, which looks for changes in BRCA1 and BRCA2, will be incorporated into the SUS—the country's unified public health network—according to a federal order published on May 13. The government has given itself 180 days to make it available.
These two genes are known as tumor suppressors. When they work properly, they produce proteins that repair damage in DNA and stop cells from multiplying in dangerous ways. When they don't work—when a mutation is present—that protection fails. According to specialists at the Brazilian Society of Mastology, which requested the test's inclusion in the public system, mutations in BRCA1 or BRCA2 can mean an 80 percent risk of developing breast cancer and a 40 percent risk of ovarian cancer. Those are not small numbers.
The test itself is called next-generation sequencing, or NGS. It's not new technology. What's new is that poor and working-class Brazilians will finally have access to it without paying out of pocket. In private clinics, the test costs between 1,000 and 3,000 reais—a sum most people cannot afford. The public system has been slow to adopt it, leaving genetic testing as something available mainly to those with money.
The decision matters because early detection of these mutations allows people to take preventive action before cancer develops. Someone who knows they carry a BRCA mutation can choose to have risk-reducing surgery, can enter intensive monitoring programs, and can make informed decisions about their own body and future. These interventions can catch cancer earlier if it does develop, and they can spare people from the far more expensive and brutal treatments that come later. The calculus is simple: prevention is cheaper and less destructive than treatment.
The test became internationally famous in 2013 when the actress Angelina Jolie revealed that she had discovered a BRCA1 mutation and had chosen to have a preventive mastectomy. Her decision brought the genes into public conversation and made clear that this was not a rare or obscure concern. Thousands of people carry these mutations without knowing it, and many of them have no way to find out.
The Brazilian Society of Mastology has already signaled that this is just the beginning. They want the public system to expand genetic counseling, to add testing for other hereditary cancer genes beyond BRCA1 and BRCA2, and to make preventive surgeries and follow-up care more accessible. The initial rollout will focus on people with suspected hereditary cancer, but the door is now open to broader implementation.
For the next six months, the machinery of the public health system will work to set up the infrastructure to offer this test. Hospitals and clinics will need to be trained, equipment will need to be installed, and protocols will need to be established. When it launches, it will change the calculus for thousands of Brazilians who have lived with the fear of inherited cancer risk but no way to know if they actually carry it.
Citas Notables
The decision represents a landmark for patients served by the SUS, especially those with family history and suspected genetic predisposition to breast and ovarian cancer.— Brazilian Society of Mastology
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this test is now public instead of private?
Because knowing you carry a BRCA mutation changes everything. Right now, a woman with a family history of breast cancer might live in fear, not knowing if she's at real risk. If she can't afford the test, that fear just stays. Once it's public, she can know. And knowing lets her choose—surgery, monitoring, different life decisions.
But surgery is a big choice. Wouldn't some people rather not know?
That's fair. But the point is they get to choose. Right now, they don't even have the option. And for many people, knowing gives them power instead of just anxiety.
The article mentions Angelina Jolie. Why does that matter to a Brazilian woman in a public hospital?
It doesn't, really—except that it shows this isn't theoretical. A famous person made a choice based on this test, and it became real to people. It also means there's already a global conversation about what to do once you know. Brazil isn't inventing this from scratch.
What happens in those 180 days before the test is available?
The system has to build capacity. Train people, get equipment, figure out who qualifies, set up genetic counseling. It's not instant. But the clock is ticking now.
Is 80 percent risk the same as 80 percent certainty?
No. It means that if you carry the mutation, your lifetime chance of getting breast cancer is around 80 percent. It's not guaranteed, but it's very high. That's why prevention matters so much.
What's the next fight after this?
The Society of Mastology already said it: they want to test for other hereditary cancer genes, not just BRCA. And they want preventive surgeries and counseling to be accessible too. This is the first door opening.